Document Detail


Selective COX-2 inhibition affects fatty acids, but not COX mRNA expression in patients with FAP.
MedLine Citation:
PMID:  20593240     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Familial adenomatous polyposis (FAP) provides a model for sporadic colorectal cancer development. Cyclooxygenase (COX) inhibition may ameliorate polyp development, but rofecoxib was withdrawn due to cardiovascular side effects. Although this selective COX-2 inhibitor, like diet, may alter the fatty acid and eicosanoid pattern, data on the potential alteration in tissues after use, are scarce. The aims were to study if rofecoxib might influence the fatty acid distribution in serum phospholipids and duodenal lesions, mRNA for COX-1 and COX-2 in leucocytes and duodenal lesions, and finally plasma levels of PGE(2) in a randomized, double-blind, placebo controlled study (n = 38). Significant reductions were found for essential fatty acid index both in serum phospholipids (P = 0.01, 95% CI = -0.9; -0.1), and in duodenal lesions (P = 0.04, 95 CI % = -0.9; -0.1) after treatment. No treatment effects were found on the COX mRNA expression, or in the plasma PGE(2) levels. Dietary AA/EPA ratio was inversely associated with all the indicators of EFA status (all P < 0.01). These findings suggest that the effects of COX chemoprevention should be further investigated in FAP and that dietary needs should be included in the treatment of FAP.
Authors:
Kari Almendingen; Laila N Larsen; Olav Fausa; Jorunn Bratlie; Arne T Høstmark; Lars Aabakken
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Familial cancer     Volume:  9     ISSN:  1573-7292     ISO Abbreviation:  Fam. Cancer     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-15     Completed Date:  2011-03-15     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  100898211     Medline TA:  Fam Cancer     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  571-80     Citation Subset:  IM    
Affiliation:
Research Centre, Akershus University Hospital, 1478 Lørenskog, Norway. kari.almendingen@hiak.no
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenomatous Polyposis Coli / blood,  drug therapy,  genetics*
Adolescent
Adult
Aged
Cyclooxygenase 1 / chemistry,  genetics*
Cyclooxygenase 2 / chemistry,  genetics*
Cyclooxygenase 2 Inhibitors / therapeutic use*
Diet
Dinoprostone / blood
Double-Blind Method
Duodenal Diseases / metabolism
Enzyme-Linked Immunosorbent Assay
Fatty Acids / metabolism*
Female
Humans
Lactones / therapeutic use*
Male
Middle Aged
Phospholipids / blood
Placebos
RNA, Messenger / genetics
Reverse Transcriptase Polymerase Chain Reaction
Sulfones / therapeutic use*
Young Adult
Chemical
Reg. No./Substance:
0/Cyclooxygenase 2 Inhibitors; 0/Fatty Acids; 0/Lactones; 0/Phospholipids; 0/Placebos; 0/RNA, Messenger; 0/Sulfones; 0/rofecoxib; 363-24-6/Dinoprostone; EC 1.14.99.1/Cyclooxygenase 1; EC 1.14.99.1/Cyclooxygenase 2; EC 1.14.99.1/PTGS1 protein, human; EC 1.14.99.1/PTGS2 protein, human
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sources of history for "a psychology of verbal communication".
Next Document:  The Number of Axillary Lymph Nodes Involved with Metastatic Breast Cancer Does not Affect Outcome as...